Role of serum thyroglobulin as a surrogate marker in evaluating outcome following radioiodine therapy in differentiated thyroid cancer

Conclusions: Serum level of thyroglobulin reflects the thyroid tissue burden in the body, hence can be used successfully to evaluate the disease burden at presentation, monitor the recurrences and progression of disease before and after radioioiodine therapy in differentiated thyroid cancer.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Endocrinology (Clinical Therapy) Posters Source Type: research